AVADEL PHARMACEUTICALS PLC - Common Stock (AVDL)

Historical Holders from Q1 2023 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
AVDL on Nasdaq
Shares outstanding
96,489,844
Price per share
$21.55
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
79,038,191
Holdings value
$1,206,764,793
% of all portfolios
0%
Share change
-1,894,250
Value change
-$18,845,555
Average buys %
+0%
Average sells %
-0%
Number of holders
182
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of AVADEL PHARMACEUTICALS PLC - Common Stock (AVDL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 7.7% -32% $113,451,794 -$56,535,847 7,429,718 -33% JANUS HENDERSON GROUP PLC 30 Sep 2025
BlackRock, Inc. 7% $63,851,286 6,742,480 BlackRock, Inc. 30 Jun 2025
Two Seas Capital LP 6.4% +26% $91,156,646 +$17,899,736 6,155,074 +24% Two Seas Capital LP 30 Jun 2025
BRANDES INVESTMENT PARTNERS, LP 5.9% $40,431,963 5,670,682 BRANDES INVESTMENT PARTNERS, LP 31 Mar 2025
VANGUARD GROUP INC 5.7% $52,693,533 5,564,259 The Vanguard Group 30 Jun 2025
As of 30 Sep 2025, AVADEL PHARMACEUTICALS PLC - Common Stock (AVDL) has 182 institutional shareholders filing 13F forms. They hold 79,038,191 shares of 96,489,844 outstanding shares (82%) .

Top 25 institutional shareholders own 67% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 7.7% 7,429,718 -33% 0.05% $113,425,183
BlackRock, Inc. 7.2% 6,973,658 +2.5% 0% $106,487,759
VANGUARD GROUP INC 5.8% 5,606,282 +0.76% 0% $85,607,927
BRANDES INVESTMENT PARTNERS, LP 5.6% 5,444,803 -16% 0.67% $83,142,141
Two Seas Capital LP 5.6% 5,369,082 -13% 4.9% $81,985,882
GENDELL JEFFREY L 5.5% 5,314,810 +2.7% 1.5% $81,157,148
Polar Capital Holdings Plc 4.1% 3,999,338 0% 0.29% $61,069,891
Vivo Capital, LLC 2.8% 2,684,109 0% 3.3% $40,986,344
STATE STREET CORP 2.4% 2,292,607 +11% 0% $35,008,109
WEALTH EFFECTS LLC 2.4% 2,288,813 -2.8% 11% $34,950,169
MORGAN STANLEY 2.3% 2,258,682 +89% 0% $34,490,073
GEODE CAPITAL MANAGEMENT, LLC 2.3% 2,175,777 +0.31% 0% $33,229,414
TANG CAPITAL MANAGEMENT LLC 2.2% 2,097,500 0% 1.2% $32,028,825
KENNEDY CAPITAL MANAGEMENT LLC 1.7% 1,626,818 +66% 0.55% $24,841,511
BANK OF AMERICA CORP /DE/ 1.4% 1,338,742 +828% 0% $20,442,590
CITADEL ADVISORS LLC 1.1% 1,057,886 -31% 0.01% $16,153,919
Krensavage Asset Management, LLC 0.99% 955,860 -0.31% 6.2% $14,596,000
Woodline Partners LP 0.93% 897,086 0% 0.06% $13,698,503
NORTHERN TRUST CORP 0.89% 856,841 +2.1% 0% $13,083,963
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.83% 799,483 +1.7% 0% $12,208,105
DEUTSCHE BANK AG\ 0.78% 754,378 +7.3% 0% $11,519,352
Tri Locum Partners LP 0.75% 724,859 -29% 2.5% $11,068,597
NEUBERGER BERMAN GROUP LLC 0.71% 688,988 +1.6% 0.01% $10,520,847
UBS Group AG 0.7% 677,981 -23% 0% $10,352,770
SAMSARA BIOCAPITAL, LLC 0.7% 675,504 0% 1.3% $10,314,946

Institutional Holders of AVADEL PHARMACEUTICALS PLC - Common Stock (AVDL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 51,834 $1,116,636 +$1,085,150 $21.55 4
2025 Q3 79,038,191 $1,206,764,793 -$18,845,555 $15.27 182
2025 Q2 80,502,710 $712,425,370 +$33,247,761 $8.85 166
2025 Q1 77,015,539 $605,345,572 -$36,024,856 $7.83 169
2024 Q4 78,672,884 $827,002,499 +$46,334,126 $10.51 153
2024 Q3 73,371,084 $962,302,493 +$83,134,495 $13.12 176
2024 Q2 66,234,107 $931,470,746 +$905,735,305 $14.06 143
2024 Q1 1,624,846 $27,443,649 +$27,443,647 $16.89 7
2023 Q2 0 $0 -$4,287 0
2023 Q1 468 $4,287 $0 $9.16 1